Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.

Circulation. Heart failure - 1 May 2015

Maurer Mathew S, Grogan Donna R, Judge Daniel P, Mundayat Rajiv, Packman Jeff, Lombardo Ilise, Quyyumi Arshed A, Aarts Janske, Falk Rodney H

Abstract excerpt

BACKGROUND: Transthyretin (TTR) amyloidosis is a progressive systemic disorder caused by misfolded TTR monomers that cumulatively deposit in the heart and systemically as amyloid. METHODS AND RESULTS: This phase 2 open-label trial evaluated the stabilization of TTR tetramers using 20 mg of tafamidis daily at week 6 (primary end point), month 6, and month 12, as well as safety of tafamidis treatment and efficacy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyloid Neuropathies, Familial
Share to Cardiomyopathies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Administration Schedule

Share to Myocardium

Share to Prealbumin

Share to Protein Multimerization

Share to Protein Stability

Share to Protein Structure, Quaternary

Source

Identifiers

PMID: 25872787
DOI: 10.1161/CIRCHEARTFAILURE.113.000890

Genes

TTR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.PMID 25872787Read ↗

Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis.Semantic proximity Read ↗

Transthyretin Amyloid Cardiomyopathy Treatment: An Updated ReviewSemantic proximity Read ↗

Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area.Semantic proximity Read ↗

Disease-Modifying Treatments for Transthyretin Amyloidosis.Semantic proximity Read ↗

A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis.Semantic proximity Read ↗

Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.Semantic proximity Read ↗

Pathogenic Characterization of a Novel G47R Transthyretin Mutation in Early-Onset Amyloid Cardiomyopathy.Semantic proximity Read ↗

Tafamidis for transthyretin amyloidosis.Semantic proximity Read ↗

TTR (Transthyretin) Stabilizers Are Associated With Improved Survival in Patients With TTR Cardiac Amyloidosis.Semantic proximity Read ↗

Diagnosis and Treatment of Transthyretin Cardiac Amyloidosis. Progress and Hope.Semantic proximity Read ↗

Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis.Semantic proximity Read ↗

Emerging, novel gene-modulating therapies for transthyretin amyloid cardiomyopathySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.